An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Single-dose Pharmacokinetics of AL-335
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2017
At a glance
- Drugs AL 335 (Primary)
- Indications Renal impairment
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 20 Oct 2016 Planned End Date changed from 1 Mar 2017 to 1 Nov 2017.
- 27 Sep 2016 Status changed from not yet recruiting to recruiting.
- 23 Sep 2016 New trial record